DLG Group sells VitaLys

DLG Group has sold VitaLys in Esbjerg, Denmark to the biotech company Glycom who will invest a large, three-digit million DKK amount and increase the manufacturing capacity and research with a significant number of new jobs.

VitaLys has been sold as a part of DLG's strategy to focus on the core business. DLG has found a strong partner to ensure the continued development of VitaLys.

It is now managed with Glycom that focuses on the production of human milk oligosaccharides (HMO) - a major component of human breast milk. It will be the first commercial large scale production of HMO to be used in the production of infant formulas.

"It is positive for VitaLys and the Esbjerg area in Denmark. The sale drives VitaLys into the top level of global biotech, and we are happy to be able to contribute to the development by handing over VitaLys to an attractive buyer. Glycom will invest a large three-digit million amount and increase the manufacturing capacity and research with a significant number of new jobs," says Vagn Hundebøll, vice-president of DLG Group in charge of Production & Logistics.